Jonathan Juco

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro, Hyun Cheol Chung, Veena Shankaran et al. · The Lancet Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifer H. Yearley, Christopher J. Gibson, Ni Yu et al. · Clinical Cancer Research · 2017 · 604 citations

Life Sciences, Immunology, Oncology +17

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Karina Kulangara, Nancy R. Zhang, Ellie Corigliano et al. · Archives of Pathology & Laboratory Medicine · 2018 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

Elizabeth R. Plimack, Joaquim Bellmunt, Shilpa Gupta et al. · The Lancet Oncology · 2017 · 333 citations

Medicine, Oncology, Pharmacology +11

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

Janis M. Taube, Güray Aktürk, Michael Angelo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 288 citations · Full text

Medicine, Oncology, Pathology +17